TY - JOUR
KW - 3383:Drug & Alcohol Rehabilitation
KW - Addiction Severity Index
KW - Adulthood (18 yrs & older)
KW - article
KW - Beck Anxiety Inventory
KW - Beck Depression Inventory
KW - Brief Pain Inventory
KW - buprenorphine
KW - buprenorphine taper duration
KW - Drug Abuse
KW - Drug Rehabilitation
KW - Empirical Study
KW - Fagerstrom Test for Nicotine Dependence
KW - Human
KW - Michigan Alcoholism Screening Test
KW - Opiates
KW - Outpatient
KW - Prescription Drugs
KW - prescription opioid abusers
KW - Public Health
KW - Quantitative Study
KW - Treatment Effectiveness Evaluation
KW - treatment evaluation
KW - Treatment Outcome/Clinical Trial
KW - US
AU - Stacey C. Sigmon
AU - Kelly E. Dunn
AU - Kathryn Saulsgiver
AU - Mollie E. Patrick
AU - Gary J. Badger
AU - Sarah H. Heil
AU - John R. Brooklyn
AU - Stephen T. Higgins
A1 - 
BT - JAMA Psychiatry
C5 - Opioids & Substance Use
CP - 12
IS - 12
JF - JAMA Psychiatry
PB - American Medical Association
PY - 2013
SN - 2168-622X, 2168-622X
SP - 1347
EP - 1354
EP - 
T1 - A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
T2 - JAMA Psychiatry
TI - A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
U1 - Opioids & Substance Use
VL - 70
VO - 2168-622X, 2168-622X
Y1 - 2013
ER -